| 1 |
Du JJ, Su Z, Yu H, Qin S, Wang D. From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy. Front Chem 2022;10:1107600. [PMID: 36733612 DOI: 10.3389/fchem.2022.1107600] [Reference Citation Analysis]
|
| 2 |
Li T, Qian C, Gu Y, Zhang J, Li S, Xia N. Current progress in the development of prophylactic and therapeutic vaccines. Sci China Life Sci 2022;:1-32. [PMID: 36469218 DOI: 10.1007/s11427-022-2230-4] [Reference Citation Analysis]
|
| 3 |
Abd-Aziz N, Poh CL. Development of Peptide-Based Vaccines for Cancer. J Oncol 2022;2022:9749363. [PMID: 35342400 DOI: 10.1155/2022/9749363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 5 |
Kumai T, Yamaki H, Kono M, Hayashi R, Wakisaka R, Komatsuda H. Antitumor Peptide-Based Vaccine in the Limelight. Vaccines (Basel) 2022;10:70. [PMID: 35062731 DOI: 10.3390/vaccines10010070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 7 |
Mukhin VE, Konstantinova YS, Gimadiev RR, Mazurchik NV. Horizons of development of immunotherapy for malignant liver tumors. jour 2021. [DOI: 10.31146/1682-8658-ecg-191-7-81-89] [Reference Citation Analysis]
|
| 8 |
Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif 2021;54:e13025. [PMID: 33754407 DOI: 10.1111/cpr.13025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 9 |
Hsu YC, Cheng JC. Perspectives of Radiotherapy in Immuno-oncology Era. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_23] [Reference Citation Analysis]
|
| 10 |
Wang J, Li Z, Wang Z, Yu Y, Li D, Li B, Ding J. Nanomaterials for Combinational Radio–Immuno Oncotherapy. Adv Funct Mater 2020;30:1910676. [DOI: 10.1002/adfm.201910676] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 11 |
Wang M, Tong Y, Luo Q, Hu S. Study of ATP borate ester effects on cell sensitization to radiation emitted by a nuclear reactor. NUCL SCI TECH 2020;31. [DOI: 10.1007/s41365-019-0713-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 12 |
Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology 2019;8:e1638212. [PMID: 31646087 DOI: 10.1080/2162402X.2019.1638212] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 20.3] [Reference Citation Analysis]
|
| 13 |
Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front Immunol 2018;9:3176. [PMID: 30719026 DOI: 10.3389/fimmu.2018.03176] [Cited by in Crossref: 130] [Cited by in F6Publishing: 145] [Article Influence: 32.5] [Reference Citation Analysis]
|
| 14 |
Galati D, Zanotta S. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy 2018;20:1309-23. [PMID: 30360963 DOI: 10.1016/j.jcyt.2018.09.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 15 |
Sun L, Hao Y, Wang Z, Zeng Y. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines. Viruses 2018;10:E145. [PMID: 29570629 DOI: 10.3390/v10040145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
